CM Hospitalar S/A (BVMF:VVEO3)
Brazil · Delayed Price · Currency is BRL | Market Cap | 385.29M +2.5% |
| Revenue (ttm) | 11.61B +1.7% |
| Net Income | 20.17M |
| EPS | n/a |
| Shares Out | 315.81M |
| PE Ratio | 19.11 |
| Forward PE | 10.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 783,100 |
| Open | 1.220 |
| Previous Close | 1.220 |
| Day's Range | 1.190 - 1.230 |
| 52-Week Range | 0.830 - 1.860 |
| Beta | 0.61 |
| Analysts | Sell |
| Price Target | 1.43 (+16.26%) |
| Earnings Date | Aug 11, 2026 |
About CM Hospitalar S/A
CM Hospitalar S/A engages in the distribution of hospital materials, medicines, and nutrition products in Brazil. The company offers material products for cardiac, surgical, urinary, diagnosis, sterilization, wound management, hygiene and protection, infusion, clinical nutrition, orthopedic, and respiratory; and medications, such as painkillers, anesthetics, anti-allergy, antibiotics, antiemetics, antifungals, anti-inflammatory, special control, several, and oncology. It also provides materials for respiratory assistance, therapy, anti-inflamma... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for VVEO3 stock is "Sell." The 12-month stock price target is R$1.43, which is an increase of 16.26% from the latest price.
News
CM Hospitalar S/A Earnings Call Transcript: Q1 2026
Q1 saw modest revenue growth but strong margin and EBITDA improvements, driven by a selective commercial strategy and operational discipline. Cash generation was positive despite seasonal challenges, leverage declined, and the competitive environment supported margin gains in key segments.
CM Hospitalar S/A Earnings release: Q1 2026
CM Hospitalar S/A released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
CM Hospitalar S/A Slides: Q1 2026
CM Hospitalar S/A has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 15, 2026.
CM Hospitalar S/A Earnings Call Transcript: Q4 2025
Operational discipline and selective contract strategy led to resumed growth and margin expansion in Q4 2025. Record cash generation and improved leverage position the company for continued efficiency and profitability focus in 2026.
CM Hospitalar S/A Earnings release: Q4 2025
CM Hospitalar S/A released its Q4 2025 earnings on March 6, 2026, summarizing the period's financial results.
CM Hospitalar S/A Slides: Q4 2025
CM Hospitalar S/A has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 6, 2026.
CM Hospitalar S/A Earnings Call Transcript: Q3 2025
Gross margin and EBITDA margin improved year-over-year, with strong cash generation and reduced net debt. Operational focus remains on efficiency, working capital, and disciplined growth, especially in hospitals and clinics, with further margin gains expected.
CM Hospitalar S/A Earnings release: Q3 2025
CM Hospitalar S/A released its Q3 2025 earnings on November 12, 2025, summarizing the period's financial results.
CM Hospitalar S/A Slides: Q3 2025
CM Hospitalar S/A has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 12, 2025.
CM Hospitalar S/A Earnings Call Transcript: Q2 2025
Q2 2025 saw 2.5% revenue growth and 6.8% gross profit increase, with margin expansion driven by contract renegotiations and strong retail and vaccine performance. Leverage improved to 4.33x, and cash generation remains a key focus for H2.
CM Hospitalar S/A Earnings release: Q2 2025
CM Hospitalar S/A released its Q2 2025 earnings on August 13, 2025, summarizing the period's financial results.
CM Hospitalar S/A Slides: Q2 2025
CM Hospitalar S/A has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 13, 2025.